Galectin Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Rhea-AI Summary

Galectin Therapeutics (NASDAQ:GALT), a leader in galectin protein-targeted therapeutics, has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York. The company's presentation is scheduled for September 8, 2025, at 1:00 PM ET.

CEO Joel Lewis and CMO Dr. Khurram Jamil will be available for one-on-one meetings during the conference. Investors can access the presentation through a live webcast, which will also be archived on the company's investor relations website.

NORCROSS, Ga., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the company management will participate in the H.C. Wainwright 27^th Annual Global Investment Conference, taking place September 8-10, 2025 in New York, NY.

H.C. Wainwright 27^th Annual Global Investment Conference
Company presentation: September 8, 2025, at 1:00 PM ET.
Webcast: HERE
The live and archived webcast will also be available on the Events & Presentations page in the investors section of the Company’s website.

Additionally, Galectin management team, including Joel Lewis, Chief Executive Officer and Khurram Jamil, M.D., Chief Medical Officer, will be available for one-on-one meetings during the conference. Interested investors should contact their representative at H.C. Wainwright.

About Galectin Therapeutics
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin’s lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH) with cirrhosis, the most advanced form of MASH-related fibrosis. Liver cirrhosis is one of the most pressing medical needs and a significant drug development opportunity. Additional development programs are in treatment of combination immunotherapy for advanced head and neck cancers and other malignancies. Advancement of these additional clinical programs is largely dependent on finding a suitable partner. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at www.galectintherapeutics.com.

Company Contact:

Jack Callicutt, Chief Financial Officer
(678) 620-3186
ir@galectintherapeutics.com

Investors Relations Contact:
Kevin Gardner
kgardner@lifesciadvisors.com

Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc. Belapectin is the USAN assigned name for Galectin Therapeutics’ galectin-3 inhibitor belapectin.

FAQ

When is Galectin Therapeutics (GALT) presenting at the H.C. Wainwright Conference 2025?

Galectin Therapeutics will present on September 8, 2025, at 1:00 PM ET at the H.C. Wainwright Global Investment Conference in New York.

How can investors watch Galectin Therapeutics' (GALT) H.C. Wainwright presentation?

Investors can watch the presentation via live webcast, which will also be available as an archive on the Events & Presentations page in the investors section of the company's website.

Who will represent Galectin Therapeutics (GALT) at the H.C. Wainwright Conference?

Joel Lewis, Chief Executive Officer, and Dr. Khurram Jamil, Chief Medical Officer, will represent the company and be available for one-on-one meetings.

How can investors schedule meetings with Galectin Therapeutics (GALT) management?

Interested investors should contact their H.C. Wainwright representative to schedule one-on-one meetings with the management team.